BRD4 acts as an epigenetic reader to regulate gene transcription. It represents a valid therapeutic target in cancer, and several selective and potent small molecule inhibitors have been discovered. A study by Le et al. (2020) published in Journal of Investigative Dermatology (2020) demonstrates that BRD4 inhibition reduces the invasive behavior of melanoma cells associated with matrix metalloproteinase-2 downregulation and increases phagocytosis by myeloid cells through SIRP alpha downregulation.Experimental cancer immunology and therap
BET family proteins are novel therapeutic targets for cancer and inflammation and represent the firs...
Epigenetic pathways can regulate gene expression by controlling and interpreting chromatin modificat...
The Bromodomain (BRD4) and extra-terminal (BET) protein family are reversible; lysine-acetylated epi...
Epigenetic regulation of gene expression plays essential roles in controlling normal cellular functi...
Post-translational modifications have been identified to be of great importance in cancers and lysin...
Melanoma accounts for the majority of all skin cancer-related deaths and only 1/3rd of melanoma pati...
Abstract Transcriptional super-enhancers and the BET bromodomain protein BRD4 are emerging as critic...
The transcriptional regulator BRD4 has been shown to be important for the expression of several onco...
Post-translational modifications have been identified to be of great importance in cancers and lysin...
Bromodomain 4 (BRD4) is an epigenetic regulator that, when inhibited, has anti-cancer effects. In th...
BET family proteins are novel therapeutic targets for cancer and inflammation and represent the firs...
Background: Previously, we used inhibitors blocking BET bromodomain binding proteins (BRDs) in Ewing...
BET family proteins are novel therapeutic targets for cancer and inflammation and represent the firs...
Chromatin regulators have become attractive targets for cancer therapy, but it is unclear why inhibi...
Abstract BRD4, member of the Bromodomain and Extraterminal (BET) protein family, is largely acknowle...
BET family proteins are novel therapeutic targets for cancer and inflammation and represent the firs...
Epigenetic pathways can regulate gene expression by controlling and interpreting chromatin modificat...
The Bromodomain (BRD4) and extra-terminal (BET) protein family are reversible; lysine-acetylated epi...
Epigenetic regulation of gene expression plays essential roles in controlling normal cellular functi...
Post-translational modifications have been identified to be of great importance in cancers and lysin...
Melanoma accounts for the majority of all skin cancer-related deaths and only 1/3rd of melanoma pati...
Abstract Transcriptional super-enhancers and the BET bromodomain protein BRD4 are emerging as critic...
The transcriptional regulator BRD4 has been shown to be important for the expression of several onco...
Post-translational modifications have been identified to be of great importance in cancers and lysin...
Bromodomain 4 (BRD4) is an epigenetic regulator that, when inhibited, has anti-cancer effects. In th...
BET family proteins are novel therapeutic targets for cancer and inflammation and represent the firs...
Background: Previously, we used inhibitors blocking BET bromodomain binding proteins (BRDs) in Ewing...
BET family proteins are novel therapeutic targets for cancer and inflammation and represent the firs...
Chromatin regulators have become attractive targets for cancer therapy, but it is unclear why inhibi...
Abstract BRD4, member of the Bromodomain and Extraterminal (BET) protein family, is largely acknowle...
BET family proteins are novel therapeutic targets for cancer and inflammation and represent the firs...
Epigenetic pathways can regulate gene expression by controlling and interpreting chromatin modificat...
The Bromodomain (BRD4) and extra-terminal (BET) protein family are reversible; lysine-acetylated epi...